These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 21733508

  • 1. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
    Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE.
    Fertil Steril; 2011 Aug; 96(2):501-504.e2. PubMed ID: 21733508
    [Abstract] [Full Text] [Related]

  • 2. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, Matíes M, Escobar-Morreale HF.
    Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
    [Abstract] [Full Text] [Related]

  • 5. Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women.
    Cheang KI, Essah PA, Sharma S, Wickham EP, Nestler JE.
    Fertil Steril; 2011 Aug; 96(2):353-359.e1. PubMed ID: 21676394
    [Abstract] [Full Text] [Related]

  • 6. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
    Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC.
    Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
    [Abstract] [Full Text] [Related]

  • 7. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [Abstract] [Full Text] [Related]

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 9. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 10. The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study.
    Bodur S, Dundar O, Kanat-Pektas M, Kinci MF, Tutuncu L.
    Taiwan J Obstet Gynecol; 2018 Jun; 57(3):411-416. PubMed ID: 29880175
    [Abstract] [Full Text] [Related]

  • 11. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
    Ibáñez L, De Zegher F.
    Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
    [Abstract] [Full Text] [Related]

  • 12. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
    Soldat-Stanković V, Popović-Pejičić S, Stanković S, Prtina A, Malešević G, Bjekić-Macut J, Livadas S, Ognjanović S, Mastorakos G, Micić D, Macut D.
    J Endocrinol Invest; 2022 Mar; 45(3):583-595. PubMed ID: 34665453
    [Abstract] [Full Text] [Related]

  • 13. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M, Kamenov Z, Kolarov G, Zakharieva S, Khristov V, Atanasova I, Shigarminova R, Milcheva B, Genchev G.
    Akush Ginekol (Sofiia); 2006 Mar; 45(7):16-28. PubMed ID: 17489164
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ.
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [Abstract] [Full Text] [Related]

  • 15. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO.
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [Abstract] [Full Text] [Related]

  • 16. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M, Kitchens CS, Khan FY.
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [Abstract] [Full Text] [Related]

  • 17. Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
    Cheng F, Zhao L, Wu Y, Huang T, Yang G, Zhang Z, Wu Y, Jia F, Wu J, Chen C, Liu D.
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):386-93. PubMed ID: 26387747
    [Abstract] [Full Text] [Related]

  • 18. Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study.
    Morotti E, Giovanni Artini P, Persico N, Battaglia C.
    Gynecol Endocrinol; 2019 Oct; 35(10):854-861. PubMed ID: 31081406
    [Abstract] [Full Text] [Related]

  • 19. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
    Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
    [Abstract] [Full Text] [Related]

  • 20. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.